Dan Zandberg
Clinical trials sponsored by Dan Zandberg, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Could changing when chemo is given boost immunotherapy for head and neck cancer? Results expected Dec 2026 (estimated)
-
New drug cocktail shows promise in shrinking head and neck tumors before surgery
Disease control OngoingThis study tests whether giving immune-boosting drugs before surgery can help shrink head and neck cancer tumors. About 80 adults with advanced but removable cancer will receive either nivolumab alone or combined with relatlimab or ipilimumab. Researchers will monitor side effect…
Phase 2 • Sponsor: Dan Zandberg • Aim: Disease control
Last updated Sep 10, 2026 04:00 UTC
-
Experimental drug ARRY-614 paired with immunotherapy shows promise in early cancer trial
Disease control OngoingThis study tests an experimental drug called ARRY-614 combined with standard immunotherapies (nivolumab or nivolumab plus ipilimumab) in people with advanced solid tumors, including lung, head and neck, kidney, and skin cancers. The first part of the trial finds the safest dose, …
Phase 1/2 • Sponsor: Dan Zandberg • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC